CN105560257A - Novel drug for treating bacterial infection - Google Patents
Novel drug for treating bacterial infection Download PDFInfo
- Publication number
- CN105560257A CN105560257A CN201610002241.9A CN201610002241A CN105560257A CN 105560257 A CN105560257 A CN 105560257A CN 201610002241 A CN201610002241 A CN 201610002241A CN 105560257 A CN105560257 A CN 105560257A
- Authority
- CN
- China
- Prior art keywords
- medicine
- younghusbandii
- incarvillea
- compd
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a novel drug for treating bacterial infection. The invention provides a drug containing an incarvillea younghusbandii phenylpropanoid glycoside compound (A). The drug is used to treat bacterial infection, the bacteria comprise escherichia coli, staphylococcus aureus, candida albicans, and pseudomonas aeruginosa, and the drug can also be used to treat dermatitis.
Description
Technical field
The present invention relates to medicinal chemistry arts, particularly, relate to the purposes of Incarvillea younghusbandii phenylpropanoid glycoside A in treatment bacteriological infection.
Background technology
Hide POLO Hua Shi China distinctive species in Qinghai-Tibet Platean, be born in alpine scrub meadow or the alpine meadow of height above sea level 3600-5400 rice.Known Tibetan POLO flower having enrich blood foster the spirit of nobility, the effect such as expelling wind and removing dampness.From Tibetan POLO is spent, isolate Incarvillea younghusbandii phenylpropanoid glycoside compound, comprise Incarvillea younghusbandii phenylpropanoid glycoside compd A and Incarvillea younghusbandii phenylpropanoid glycoside compd B.Existing scientific achievement shows that Incarvillea younghusbandii phenylpropanoid glycoside compound has the effect such as antioxidation, treatment atherosclerosis.CN101264094A(application number 200810044220.9) describe extracting method and the structural formula of Incarvillea younghusbandii phenylpropanoid glycoside compound, the document quotes in full the part as present specification at this.
Present invention applicant, by studying for many years, finds that Incarvillea younghusbandii phenylpropanoid glycoside compd A has good bacterial-infection resisting and anti-dermatitis is active.
Summary of the invention
One aspect of the present invention, provides a kind of medicine, comprising Incarvillea younghusbandii phenylpropanoid glycoside compd A.
Another aspect of the present invention, provides the purposes of Incarvillea younghusbandii phenylpropanoid glycoside compd A in the medicine of preparation treatment bacteriological infection.
Another aspect of the present invention, described antibacterial comprises escherichia coli, staphylococcus aureus, Candida albicans and Pseudomonas aeruginosa.
Another aspect of the present invention, provides the purposes of Incarvillea younghusbandii phenylpropanoid glycoside compd A in the medicine of preparation treatment dermatitis.
Another aspect of the present invention, meets subject patient and comprises mammal and birds.
Another aspect of the present invention, meeting subject patient is people.
Medicine of the present invention can be any medicine type known in the art, includes but not limited to tablet, capsule, drop pill, injection, freeze-dried powder, decoction, slow releasing preparation, powder, granule, suppository, aerosol etc.
Useful in preparing drug formulations of the present invention adopts excipient substance known in the art, comprises binding agent, filler, lubricant, diluent, solvent, slow-release material etc.Include but not limited to starch, dextrin, lactose, mannitol, microcrystalline Cellulose, hypromellose, polyvidone, cross-linking sodium carboxymethyl cellulose, Pulvis Talci, stearic acid, poloxamer, ethyl cellulose, acrylic resin etc.
Medicine of the present invention can be used by topical and systemic administration.Local administration comprises topical.Systemic administration comprises oral, parenteral (such as intravenous, intramuscular, subcutaneous or rectum), and other system route of administration.In systemic administration, first this reactive compound arrives blood plasma, is then distributed in target tissue.Topical and oral administration are route of administration preferred for the present invention.
Following examples set forth the present invention further.These embodiments are only intended to the present invention is described, and should not be understood to restricted.
Detailed description of the invention
Embodiment 1:
Get Incarvillea younghusbandii phenylpropanoid glycoside compd A 100g, add starch dust 160g, with the mixing of equal increments method, with the ethanol of 80%, make granule, dry, granulate, mixing, add Pulvis Talci 4g, magnesium stearate 1.6g, namely tabletting obtains (1000).
Embodiment 2:
Get Incarvillea younghusbandii phenylpropanoid glycoside compd A 200g, add starch dust 200g, Pulvis Talci 10g, magnesium stearate 5g, make granule, dry, incapsulates (1000).
Embodiment 3:
Get Incarvillea younghusbandii phenylpropanoid glycoside compd A 100g, microcrystalline Cellulose 250g, crospolyvinylpyrrolidone 70g, mixing, add ethanol in proper amount and granulate, dry, granulate, is adding carboxymethyl starch sodium 8g, magnesium stearate 4g, mixing, tabletting (1000).
Embodiment 4: antibacterial effect is tested
With escherichia coli, staphylococcus aureus, Candida albicans and Pseudomonas aeruginosa for test organisms, adopt nephelometry, investigate the fungistatic effect of antibacterial.
The preparation of bacteria suspension: escherichia coli, staphylococcus aureus and Pseudomonas aeruginosa are aseptically seeded in 10ml nutrient broth medium respectively, 35 DEG C, cultivates 24h.Bacteria suspension physiological saline solution dilutes, and makes bacterial concentration reach 10
6cfu/ml.Candida albicans is aseptically seeded to 10ml and improves in Martin's fluid medium, 25 DEG C, cultivates 48h.Bacteria suspension physiological saline solution dilutes, and makes bacterial concentration reach 10
6cfu/ml.
The preparation of test liquid: take p-Hydroxybenzoate 0.2g respectively and p-Hydroxybenzoate 0.2g, phenethanol 5ml got in title (amount), be dissolved in 100ml nutrient broth medium, for escherichia coli, staphylococcus aureus and Pseudomonas aeruginosa test.Take p-Hydroxybenzoate 0.2g respectively and p-Hydroxybenzoate 0.2g, phenethanol 5ml got in title (amount), be dissolved in 100ml and improve in Martin's fluid medium, try out for Candida albicans.Get 10ml test liquid in test tube, autoclaving.Each test bacterium establishes 3 pipe test liquids (Incarvillea younghusbandii phenylpropanoid glycoside compd A low dose group, middle dosage group and high dose group), and establishes one group of control tube (blank medicine).Under aseptic condition, often prop up test tube and add bacteria suspension 0.2ml.Escherichia coli, staphylococcus aureus and Pseudomonas aeruginosa 35 DEG C, cultivate 24h, Candida albicans 25 DEG C, cultivates 48h.
According to " Chinese Pharmacopoeia 2010 version two " the antibacterial effect inspection technique guideline that annex specifies, inhibitory effect demonstration test is carried out to test liquid of the present invention.
Experimental result is as follows:
Incarvillea younghusbandii phenylpropanoid glycoside compd A low dose group 0.5mg/ml
Dosage group 2mg/ml in Incarvillea younghusbandii phenylpropanoid glycoside compd A
Incarvillea younghusbandii phenylpropanoid glycoside compd A high dose group 5mg/ml
Table 1 Incarvillea younghusbandii phenylpropanoid glycoside compd A low dose group inhibitory effect test organisms number decline lg value
Dosage group inhibitory effect test organisms number decline lg value in table 2 Incarvillea younghusbandii phenylpropanoid glycoside compd A
Table 3 Incarvillea younghusbandii phenylpropanoid glycoside compd A high dose group inhibitory effect test organisms number decline lg value
Table 4 blank group inhibitory effect test organisms number decline lg value
Table 1-4 data show, relative to blank group, Incarvillea younghusbandii phenylpropanoid glycoside compd A of the present invention basic, normal, high dosage group all has inhibitory action to each bacterioid.
Embodiment 5
The research of anti-mouse ear atopic dermatitis
1. reagent: DNF (DNFB), is dissolved in acetone-olive oil (3: 1, v/v) mixed solvent, is mixed with the solution of 0.15%w/v; Medicine of the present invention; Dexamethasone ointment (Shenzhen three nine-day periods after the winter solstice company).
2. the preparation of animal model: get male BALB/c mouse in 7 week age (body weight 18 ~ 22g), be divided into sensitization group and group of solvents at random, sensitization group 30, group of solvents 8.Allergen is not coated with 0.15%DNFB25ul and brings out dermatitis in mouse right ear both sides, acetone-olive oil (3: 1, the v/v) mixed solvent that group of solvents smears same volume (does not cause inflammation) in contrast.Observe Mus ear after one week and whether obvious tumefaction occurs, as the mark whether model is successfully prepared.
3. experiment grouping and administration: the mice of successful sensitization is divided into 3 groups at random, often organizes 8.Attack first 8 hours the last time, often organize and give Incarvillea younghusbandii phenylpropanoid glycoside compd A, the commercially available ointment of dexamethasone and adjuvant matched group (not containing active medicine) respectively, be 2mg/kg in reactive compound dosage, adjuvant matched group dosage is 2mg/kg.
4. the mensuration of observation index Mus ear thickness: test each group after last attack 6h digital display micrometer caliper (Kenta company, Singapore) measure mouse right ear thickness and with attack before Mus ear Thickness Ratio comparatively.
5. experimental result is shown in table 5.
The result of table 5. anti-mouse ear atopic dermatitis
| Sample | Mus ear thickens (micron) |
| Group of solvents | 0.5 |
| Adjuvant matched group | 95.8 |
| Incarvillea younghusbandii phenylpropanoid glycoside compd A group | 44.3 |
| The commercially available ointment of dexamethasone | 56.9 |
From table 5 data, Incarvillea younghusbandii phenylpropanoid glycoside compd A of the present invention has the significant effect suppressing mouse ear dermatitis.
Claims (10)
1. a medicine, comprising Incarvillea younghusbandii phenylpropanoid glycoside compd A.
2. medicine as claimed in claim 1, wherein pharmaceutical dosage forms is tablet, capsule, drop pill, injection, freeze-dried powder, decoction, slow releasing preparation, powder, granule, suppository or aerosol.
3. medicine as claimed in claim 1 or 2, wherein also comprises excipient substance.
4. medicine as claimed in claim 3, wherein excipient substance comprises binding agent, filler, lubricant, diluent, solvent, slow-release material.
5. medicine as claimed in claim 4, wherein excipient substance comprises starch, dextrin, lactose, mannitol, microcrystalline Cellulose, hypromellose, polyvidone, cross-linking sodium carboxymethyl cellulose, Pulvis Talci, stearic acid, poloxamer, ethyl cellulose, acrylic resin.
6. the purposes of Incarvillea younghusbandii phenylpropanoid glycoside compd A in the medicine of preparation treatment bacteriological infection.
7. purposes as claimed in claim 6, wherein said antibacterial comprises escherichia coli, staphylococcus aureus, Candida albicans and Pseudomonas aeruginosa.
8. the purposes of Incarvillea younghusbandii phenylpropanoid glycoside compd A in the medicine of preparation treatment dermatitis.
9. the purposes as described in any one of claim 6-8, meets subject patient and comprises mammal and birds.
10. purposes as claimed in claim 9, wherein meeting subject patient is people.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610002241.9A CN105560257A (en) | 2016-01-05 | 2016-01-05 | Novel drug for treating bacterial infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610002241.9A CN105560257A (en) | 2016-01-05 | 2016-01-05 | Novel drug for treating bacterial infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105560257A true CN105560257A (en) | 2016-05-11 |
Family
ID=55871276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610002241.9A Pending CN105560257A (en) | 2016-01-05 | 2016-01-05 | Novel drug for treating bacterial infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560257A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152261A (en) * | 2007-09-04 | 2008-04-02 | 北京理工大学 | Application of phenyl ethyl alcohol glycosides and xylogen glycosides component in forsythia (fruit or leaf) |
| CN101264094A (en) * | 2008-04-16 | 2008-09-17 | 西藏自治区高原生物研究所 | Incarvillea younghusbandii phenylpropanoid glycoside composition and preparation and use thereof |
| CN101654692A (en) * | 2009-08-04 | 2010-02-24 | 中山大学 | Method for producing mullein glucoside monomeric compound |
| CN102304156A (en) * | 2011-06-24 | 2012-01-04 | 浙江大东吴药业有限公司 | Phenylethanoid glycoside components, and preparation method and application thereof |
| CN102920718A (en) * | 2012-11-30 | 2013-02-13 | 苏州大学 | Application of phenylethanoid glycoside monomeric compound |
| CN103816296A (en) * | 2012-11-19 | 2014-05-28 | 苏州润新生物科技有限公司 | Callicarpa bodinieri total glycosides extract as well as preparation method and application thereof |
-
2016
- 2016-01-05 CN CN201610002241.9A patent/CN105560257A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152261A (en) * | 2007-09-04 | 2008-04-02 | 北京理工大学 | Application of phenyl ethyl alcohol glycosides and xylogen glycosides component in forsythia (fruit or leaf) |
| CN101264094A (en) * | 2008-04-16 | 2008-09-17 | 西藏自治区高原生物研究所 | Incarvillea younghusbandii phenylpropanoid glycoside composition and preparation and use thereof |
| CN101654692A (en) * | 2009-08-04 | 2010-02-24 | 中山大学 | Method for producing mullein glucoside monomeric compound |
| CN102304156A (en) * | 2011-06-24 | 2012-01-04 | 浙江大东吴药业有限公司 | Phenylethanoid glycoside components, and preparation method and application thereof |
| CN103816296A (en) * | 2012-11-19 | 2014-05-28 | 苏州润新生物科技有限公司 | Callicarpa bodinieri total glycosides extract as well as preparation method and application thereof |
| CN102920718A (en) * | 2012-11-30 | 2013-02-13 | 苏州大学 | Application of phenylethanoid glycoside monomeric compound |
Non-Patent Citations (4)
| Title |
|---|
| KAREL SMEJKAL ET AL: "Antiradical Activity of Paulownia tomentosa (Scrophulariaceae) Extracts", 《MOLECULES》 * |
| 吴娟: "藏角蒿花的化学成分研究", 《中国优秀硕士论文全文数据库医药卫生科技辑》 * |
| 宋景春 等: "《弥散性血管内凝血中西医结合治疗学》", 31 December 2014, 军事医学科学出版社 * |
| 邹国栋等: "HP L C法测定紫珠叶中毛蕊花糖苷的含量", 《药物分析杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| VATNIKOV et al. | Research on the antibacterial and antimycotic effect of the phytopreparation Farnesol on biofilm-forming microorganisms in veterinary medicine. | |
| CN103127038B (en) | The purposes of patchouli alcohol | |
| CN102573858A (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| CN108685996B (en) | A topical natural medicinal composition for preventing and treating acne, and its preparation method | |
| Paczkowska et al. | Mucoadhesive chitosan delivery system with Chelidonii herba lyophilized extract as a promising strategy for vaginitis treatment | |
| EP2881113A1 (en) | New application of pogostone | |
| CN103222978B (en) | Fu side's Sulfamethoxazole parenteral solution and preparation method | |
| CN105078934A (en) | New application of piceatannol | |
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| CN102058660A (en) | Application of patchouli oil to preparing drugs for treating bacterial infectious diseases | |
| JP2019178170A (en) | Use of patchouli extract in preparation of compositions with anti-microorganism effect | |
| Zhao et al. | Gastrodin relieves Vibrio harveyi infection by blocking hemolysin active centers | |
| Kovalev et al. | Antimicrobial activity of extracts of Iris hungarica and Iris sibirica | |
| CN105560257A (en) | Novel drug for treating bacterial infection | |
| CN103951679B (en) | A kind of cefoperazone sodium compound and pharmaceutical composition thereof | |
| CN103933350A (en) | Use of rhizoma bletillae ethyl acetate extract | |
| CN104586862A (en) | Application of N-acetylneuraminic acid monomer, N-acetylneuraminic acid hydrate or N-acetylneuraminate in external anti-inflammation medicines | |
| CN113318149B (en) | Jasminum extract and preparation method and application thereof | |
| Majumder et al. | Exploring phytochemicals as alternatives to antimicrobials-Prospects and potentials | |
| CN104800253A (en) | Use of eurycoma longifolia extract | |
| CN103622955A (en) | Application of ellagic acid to preparation of drugs for treating and preventing fungal infection of human body | |
| US9629864B2 (en) | Use of baicalin in preparation of drugs for treating acute hemolytic uremic syndrome | |
| CN102988765B (en) | Usage of rhizoma bletillae ethyl acetate extractive | |
| CN103040897B (en) | Application of Qingkailing active component radix isatidis extract in preparation of anti-multidrug-resistant bacterium medicine | |
| CN105998029A (en) | Antibacterial composite drug of levofloxacin hydrochloride for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |